Molecular Biology Reports

, Volume 46, Issue 6, pp 6617–6624 | Cite as

Dysregulation of non-histone molecule miR205 and LRG1 post-transcriptional de-regulation by SETD1A in triple negative breast cancer

  • Ezanee Azlina Mohamad HanifEmail author
Short Communication


FEC chemo-resistance in triple negative breast cancer (TNBC) remains a challenge. Therefore it is crucial to determine the right treatment regime by understanding molecular mechanisms of driver regulators involved in the progression of TNBCs. This study aims to understand SETD1A mechanisms in TNBC development in two TNBC cell lines. SETD1A was transiently transfected in MDA-MB-468 (FEC good prognosis) and Hs578T (FEC poor prognosis). Regulation of potential targets miR205, EMT marker ZEB1 and LRG1 and proliferative marker Ki-67 were tested by RqPCR to elucidate SETD1A interactions. This study displayed significant recovery of miR205 with SETD1A depletion and reduction of ZEB1 in MDA-MB-468. However, ZEB1 remained unchanged in Hs578T indicating ZEB1 regulation may be outcompeted by other mechanisms associated with aggressive cell line characteristics and the expression of endogenous ZEB1 was relatively high in Hs578T. Elevation of LRG1 and declined Ki-67 were observed by SETD1A knocked down. Enhanced expression was observed by LRG1 in Hs578T and not in MDA-MB-468 suggesting LRG1 contributed to distinct poor FEC outcome in TNBCs. The underlying mechanism of SETD1A in miR205/ZEB1/Ki-67/LRG1 axis needs further evaluation. Whether abrogation of the pathway is indeed associated with transcriptional or post-transcriptional activation in TNBC cell lines models, clearly validation in clinical samples is warranted to achieve its prognostic and therapeutic values in TNBCs.


Triple negative breast cancers TNBCs SETD1A miR205 EMT 



This study was funded by Geran Galakan Penyelidik Muda (Young Investigator Grant) (Project Code: GGPM-2017-103).


This study was funded by Geran Galakan Penyelidik Muda (Young Investigator Grant) (Project Code: GGPM-2017-103).

Compliance with ethical standards

Conflict of interest

There was no conflict of interest throughout the study.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R (2008) Triple-negative breast cancer. Curr Opin Oncol 20:614–620CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4:70–76CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Willis A, Jung EJ, Wakefield T, Chen X (2004) Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23:2330–2338CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D’Incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G, Di Leo A (2013) Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev 39:541–550CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Muller PAJ, Trinidad AG, Caswell PT, Norman JC, Vousden KH (2014) Mutant p53 regulates dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype. J Biol Chem 289:122–132CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte R, Jacquemier J, Viens P, Birnbaum D (2005) Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 65:2170–2178CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750–2767CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe J-P, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo W-L, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515–527CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge W, Carey LA, Carolina N, Hill C, Inhibition PARP (2011) “Targeted” therapy for triple negative breast cancer. Clin Cancer Res 16:4702–4710CrossRefGoogle Scholar
  10. 10.
    Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Baxter E, Windloch K, Gannon F, Lee JS (2014) Epigenetic regulation in cancer development. Cell Biosci 4:1–11CrossRefGoogle Scholar
  12. 12.
    Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E, Martinez-Delgado B, Eroles P, Climent J, Burgués O, Ferrer-Lozano J, Bosch A, Lluch A, Ribas G (2014) MicroRNA profile in very young women with breast cancer. BMC Cancer 14:529CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Liu L, Kimball S, Liu H, Holowatyj A, Yang Z-Q (2015) Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget 6:2466–2482Google Scholar
  14. 14.
    Salz T, Deng C, Pampo C, Siemann D, Qiu Y, Brown K, Huang S (2014) Histone methyltransferase hSETD1A is a novel regulator of metastasis in breast cancer. Mol Cancer Res 13:461–469CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Salz TH (2014) Novel roles for human SETD1A histone methyltransferase in regulation of canonical WNT signaling pathway, cellular proliferation and metastasisGoogle Scholar
  16. 16.
    Cheng X, Sun S, Zhong F, He K, Zhou J (2016) Knockdown of histone methyltransferase hSETD1A inhibits progression, migration, and invasion in human hepatocellular carcinoma. Oncol Res Featur Preclin Clin Cancer Ther 24:239–245Google Scholar
  17. 17.
    Hanif EA, Mullan PB, Kennedy R (2015) MiR205 is a p53/p63-dependent marker lost in poor outcome triple negative breast cancers. Eur J Cancer Care 24:24–82Google Scholar
  18. 18.
    Mayoral-Varo V, Calcabrini A, Sánchez-Bailón MP, Martín-Pérez J (2017) miR205 inhibits stem cell renewal in SUM159PT breast cancer cells. PLoS ONE 12:1–14CrossRefGoogle Scholar
  19. 19.
    Vrba L, Garbe JC, Stampfer MR, Futscher BW (2011) Epigenetic regulation of normal human mammary cell type-specific miRNAs. Genome Res 21:2026–2037CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kathryn JC, Sireesha G, Stanley VL (2012) Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 32:35–48Google Scholar
  21. 21.
    Akagi I, Miyashita M, Ishibashi O, Mishima T, Kikuchi K, Makino H, Nomura T, Hagiwara N, Uchida E, Takizawa T (2011) Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis Esophagus 24:523–530CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE 8:1–8CrossRefGoogle Scholar
  23. 23.
    Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM (2012) Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 6:458–472CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wang Z, Liao H, Deng Z, Yang P, Du N, Zhanng Y, Ren H (2013) miRNA-205 affects infiltration and metastasis of breast cancer. Biochem Biophys Res Commun 441:139–143CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhang Y, Luo Q, Wang N, Hu F, Jin H, Ge T, Wang C, Qin W (2015) LRG1 suppresses the migration and invasion of hepatocellular carcinoma cells. Med Oncol 32:1–10CrossRefGoogle Scholar
  26. 26.
    Xie ZB, Zhang YF, Jin C, Mao YS, Fu DL (2019) LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling. J Exp Clin Cancer Res 38:1–12CrossRefGoogle Scholar
  27. 27.
    Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN (2011) MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 10:507–517CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gupta I, Sareyeldin RM, Al-Hashimi I, Al-Thawadi HA, Al Farsi H, Vranic S, Al Moustafa AE (2019) Triple negative breast cancer profile, from gene to microRNA, in relation to ethnicity. Cancers (Basel) 11:1–25Google Scholar
  29. 29.
    Bhatnagar N, Li X, Padi SKR, Zhang Q, Tang MS, Guo B (2010) Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 1:1–8CrossRefGoogle Scholar
  30. 30.
    Mohamad Hanif EA, Shah SA (2018) Overview on epigenetic re-programming: a potential therapeutic intervention in triple negative breast cancers. Asian Pac J Cancer Prev 19:3341–3351CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bianchi M, Renzini A, Adamo S, Moresi V (2017) Coordinated actions of microRNAs with other epigenetic factors regulate skeletal muscle development and adaptation. Int J Mol Sci 18:1–14Google Scholar
  32. 32.
    Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R, Izzotti A (2017) Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res 7:1350–1371PubMedPubMedCentralGoogle Scholar
  33. 33.
    Tao B-B, Liu X-Q, Zhang W, Li S, Dong D, Xiao M, Zhong J (2017) Evidence for the association of chromatin and microRNA regulation in the human genome. Oncotarget 8:70958–70966PubMedPubMedCentralGoogle Scholar
  34. 34.
    Gurtan AM, Ravi A, Rahl PB, Bosson AD, Jnbaptiste CK, Bhutkar A, Whittaker CA, Young RA, Sharp PA (2013) Let-7 represses Nr6a1 and a mid-gestation developmental program in adult fibroblasts. Genes Dev 27:941–954CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gosline SJC, Gurtan AM, Jnbaptiste CK, Bosson A, Milani P, Dalin S, Matthews BJ, Yap YS, Sharp PA, Fraenkel E (2016) Elucidating microRNA regulatory networks using transcriptional, post-transcriptional and histone modification measurements. Cell Rep 14:310–319CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PAJ, Dotsch V, Kehrloesser S, Sayan BS, Giaccone G, Lowe SW, Takahashi N, Vandenabeele P, Knight RA, Levine AJ, Melino G (2012) Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. PNAS 109:15312–15317CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Zhang P, Wang L, Rodriguea-Aguayo C, Yuan Y, Debeb BG, Chen D, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Lopez-Berestein G, Sood AK, Hu Y, Ang KK, Chen J, Ma L (2015) MiR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. J Chem Inf Model 5:5671Google Scholar
  38. 38.
    Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Banin Hirata BK, Oda JMM, Losi Guembarovski R, Ariza CB, de Oliveira CEC, Watanabe MAE (2014) Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers. 2014:513158CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Zhou F, Li S, Meng H-M, Qi L-Q, Gu L (2013) MicroRNA and histopathological characterization of pure mucinous breast carcinoma. Cancer Biol Med 10:22–27PubMedPubMedCentralGoogle Scholar
  41. 41.
    Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, Kåresen R, Shama Prasada K, Rotti H, Rao R, Rao L, Eric Tang M-H, Satyamoorthy K, Lucito R, Wigler M, Dimitrova N, Naume B, Borresen-Dale A-L, Hicks JB (2011) DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol 5:77–92CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lehmann BD, Pietenpol JA (2015) Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 24(Suppl 2):S36–S40CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban N, Lubman DM (2015) Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. PLoS ONE 10:1–11Google Scholar
  44. 44.
    Ramirez-Ardila DE, Ruigrok-Ritstier K, Helmijr JC, Look MP, van Laere S, Dirix L, Berns EMJJ, Jansen MPHM (2016) LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome. Mol Oncol 10:1363–1373CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.UKM Medical Molecular Biology Institute (UMBI)University Kebangsaan Malaysia Medical CentreKuala LumpurMalaysia

Personalised recommendations